Announcement - Clontech Laboratories, Inc. Releases the SMARTer® Universal Low Input RNA Kit for Sequencing

Announcement - Clontech Laboratories, Inc. Releases the SMARTer® Universal Low
                         Input RNA Kit for Sequencing

PR Newswire

MOUNTAIN VIEW, Calif., May 1, 2013

MOUNTAIN VIEW, Calif., May 1, 2013 /PRNewswire/ -- Clontech Laboratories,
Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the
release of the SMARTer Universal Low Input RNA Kit for Sequencing. The SMARTer
Universal Low Input RNA Kit extends Clontech's NGS (Next Generation
Sequencing) solutions to include low input samples of compromised RNA. It
combines Clontech's patented SMART™ (Switching Mechanism at 5' End of RNA
Template) technology for ds cDNA synthesis with random priming, to facilitate
transcriptome sequencing (RNA-Seq) from degraded total RNA samples acquired
via common sample preparation techniques such as formaldehyde fixed paraffin
embedded tissue (FFPE) and laser capture microscopy (LCM), which result in a
loss of overall sample quality and/or yield.

Carol Lou, General Manager of Clontech Laboratories, Inc., comments: "Clontech
has already pushed the limits of RNA-Seq down to the single cell level with
our SMARTer Ultra Low RNA Kit for Illumina® Sequencing. Today, we are
expanding the applications of SMART technology to include cDNA synthesis from
samples that contain degraded RNA (e.g. FFPE or LCM samples) or
non-polyadenylated RNA. We expect the SMARTer Universal Low Input RNA Kit for
Sequencing to be a welcome addition to RNA-Seq research."

RNA-Seq has revolutionized gene expression profiling, enabling researchers to
characterize a cell's entire transcriptional activity at the nucleotide level.
This ability to analyze all expressed genes both qualitatively and
quantitatively, without assumptions (no a priori requirements for probe
design), is leading to many significant advances in the field of biomedical
research, including new findings in the fields of development, cancer
research, plant biology, and neurobiology.

The SMART protocol greatly reduces handling of the RNA sample, thereby
minimizing the risk of sample loss and preserving the original message. The
efficient incorporation of known sequences at both ends of the cDNA during
first strand synthesis enables researchers to perform the entire protocol in a
single tube, without a separate adaptor ligation step. The SMARTer Universal
Low Input RNA Kit for Sequencing broadens the applications of RNA-Seq to
include very low amounts of total RNA that are either compromised such as FFPE
and LCM samples, or are from sources that do not have polyadenylated mRNA.
Clontech plans to further expand the utility of the SMARTer kits for NGS by
combining them with other key technologies, including multiplex library
preparation

About Clontech Laboratories, Inc.
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc.,
develops, manufactures, and distributes a wide range of life science research
reagents under the Clontech® and Takara® brands. Key products include SMARTer
cDNA synthesis kits for a variety of samples and applications, including NGS;
high-performance qPCR and PCR reagents (including the Ex Taq™, LA Taq™,
Titanium®, and Advantage® enzymes); RT enzymes and SMART library construction
kits; the innovative In-Fusion® cloning system; Tet-based inducible gene
expression systems; and a range of Macherey-Nagel nucleic acid purification
tools. These and other products support applications including gene discovery,
regulation, and function; protein expression and purification; RNAi and stem
cell studies; and plant and food research. For more information, visit
www.clontech.com.

About Takara Bio Inc.
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan.
As a world leader in biotechnology research and development, Takara Bio was
the first company to market PCR technology in Japan and is also the developer
of the RetroNectin® reagent, which is used as a world-standard in gene therapy
protocols. In addition to providing research reagents and equipment to the
life science research market, Takara Bio has active research and product
development activities in the fields of gene and cell-based therapy, and
agricultural biotechnology; and is committed to preventing disease and
improving the quality of life for all people through the use of biotechnology.
Through strategic alliances with other industry leaders, the Company aims to
extend its reach around the world. More information is available at
http://www.takara-bio.com.

SOURCE Clontech Laboratories, Inc.

Website: http://www.clontech.com
Contact: Lorna Neilson, Ph.D., Director, Business Development,Clontech
Laboratories, Inc., 1290 Terra Bella Avenue,Mountain View, CA 94043,
+1-650.919.7372, lorna_neilson@clontech.com